Table 2 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
收藏NIAID Data Ecosystem2026-05-10 收录
数据链接：
官方服务：
资源简介：
Adverse events grade 2 or higher attributed to palbociclib and binimetinib (>5% of the patients).
创建时间：
2025-09-29
